NRSN חוב כולל להון NeuroSense Therapeutics, Ltd.

The market dynamics of the total debt-to-equity ratio for NeuroSense Therapeutics (NRSN) reflected in the price action is 0.00. This biopharma business generates revenue from treating nerve cell degeneration, with global sales and low costs ensuring high scalability. Risks are minimized through a broad patent portfolio and multidisciplinary trials. The impeccable reputation of NeuroSense Therapeutics within the scientific community is evidenced by the close attention paid to their methods for combating Alzheimer's and ALS.

For NeuroSense Therapeutics (NRSN), whose valuation is based on patents for ALS and Alzheimer's therapies, managing borrowed funds is critical until the FDA verdict. This metric compares total liabilities to net assets, determining the degree of financial autonomy and the risk of a liquidity gap, which clearly reflects the trend of financial dependence regarding the debt-to-equity ratio.